Provista Life Sciences LLC Announces Initiation of the BT Test(R) Validation Study in the United Kingdom
Published: Nov 12, 2008
PHOENIX--(BUSINESS WIRE)--Provista Life Sciences LLC (PLS) announced today that the National Health System’s Ethical Committee approval has been granted to proceed with a validation study of its Biomarker Translation Test (BT Test) in the United Kingdom (UK). The BT Test, a new blood test developed by Provista Life Sciences to aid healthcare providers in early breast cancer detection, will undergo a validation study in the UK to be conducted in conjunction with the Cambridge University Hospital’s (Addenbrooke’s) Breast Unit. The validation study is anticipated to begin recruitment in November 2008 and to have the study completed within the next 9 months.